Potential Abilene Convention Center renovations
ABILENE, Texas () – The Abilene City Council recently met for their annual retreat on Friday, January 31. Spending the day reflecting on projects and goals for the upcoming year. One of those projects is renovations to the Abilene Convention Center. It was in May 2024 when City Manager Robert Hanna mentioned that the Hilton DoubleTree Hotel in downtown Abilene was outperforming the Abilene Convention Center.
At the meeting, the council listened to a report made by Garfield Public/Private LLC, who were tasked in the spring of 2024 to create suggestions on what renovations are needed at the convention center to make it work hand in hand with the hotel. Lasting for generations to come. Steve Galbreath represented Garfield Public/Private LLC, sharing ideas like changes to the atrium, green room, and patio area.
The atrium creates a modern look perfect for cocktail hour or banquets. The green room renovations make it appealing for other artists and acts to visit Abilene, and the patio area serves as a space for VIP experiences or meet-the-cast social events. However, an extensive renovation will be done to the auditorium to add more aisles, update seating, and make it more ADA-friendly.
'It's very difficult to go anywhere in the convention center if you are not mobile. So right now, if you had your mom or your dad in a wheelchair and you were going to take them to a show and your seats were not in the very back, you will have to take them out the doors into the parking lot around the corner and come back in to get to that space, and that's just not acceptable,' explained Galbreath.
With the Hilton Double Tree hotel right next door, Galbreath shares that renovations to the convention center can help make these two sites work together.
'We were with John Kay and the hotel to really figure out how these two pieces work together because that's really the idea. It was to bring in this hotel convention center to maximize high-impact business for the city,' added Galbreath.
Galbreath and City Manager Robert Hanna explained competitions like Heritage Square in Abilene, revitalizing an eight-acre tract into a community space. Once construction is complete, it will feature an auditorium space.
'So, let's start with having the heritage square. I think the audience for that particular product is different than the convention space that we're talking about. You've got a highly creative, active-oriented museum and learning center that has an auditorium and auditorium space that's going to be a place for children to learn, hear from experts, and be educated. But they're really intending not to have that competitive environment. They're trying to serve a niche market that we frankly don't serve right now,' shared Hanna.
The convention center renovation plan costs about 68 million, but of course, with any construction project, numbers change as months go by. Hanna says there are many ways to go about it.
'Additional hot tax on hotel night stays, so it's not Abileneans that are paying for that. It's the people that are passing through using the facility. The other way of doing it would be asking the voters, and maybe you do both, even maybe you do the venue district, and then you ask the voters to issue bonds in the amount that would be the delta of whatever the total project costs would be,' added Hanna.
The council, taking in all these suggestions, meets again later to decide if any action will be taken. You can learn more here: Jan 31, 2025, City Council Retreat – Abilene, TX.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking place June 20-23, 2025 in Chicago, IL. Presentation details: Symposium Title: Joint ADA/IPITA Symposium: Outpacing the Immune System—Sprinting Towards Immune Protection for Cell Replacement Therapy Presentation Title: Hypoimmune Pancreatic Islet Transplantation in Adult Subjects with Type 1 Diabetes Presentation Date: Monday, June 23, 2025 Presentation Time: 9:00 – 9:20 a.m. CT Location: W192 A-C About Sana Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA and Bothell, WA. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the 'Company,' 'we,' 'us,' or 'our') within the meaning of the federal securities laws, including those related to the company's vision and expectations regarding participation in and the presentation at the 85th Annual American Diabetes Association Scientific Sessions, including the content of such presentation. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'design,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'positioned,' 'potential,' 'predict,' 'seek,' 'should,' 'target,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company's current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's Securities and Exchange Commission reports, including but not limited to its Quarterly Report on Form 10-Q dated May 8, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. Investor Relations & Media:Nicole
Yahoo
3 hours ago
- Yahoo
Nasdaq confirms XRP, SOL, ADA, and XLM in benchmark index via new SEC filing
Nasdaq confirms XRP, SOL, ADA, and XLM in benchmark index via new SEC filing originally appeared on TheStreet. Nasdaq has officially filed an SEC Form 8-K for the Hashdex Nasdaq Crypto Index US ETF, confirming it has reconstituted its benchmark index to include four new digital assets: Cardano (ADA), Solana (SOL), Stellar Lumens (XLM), and XRP. These coins are now part of the Nasdaq Crypto US Settlement Price Index (NCIUS), which the ETF uses as its benchmark. According to the filing dated June 2, this update marks a significant step toward broader crypto representation in institutional investment products. However, despite the change, the Trust will continue to hold only Bitcoin and Ethereum for now, due to its existing listing restrictions. 'Notwithstanding the changes to the NCI US, the Trust will continue to hold only BTC and ETH… due to the limitations of the Trust's currently approved listing rule,' the filing states. The update was disclosed in a Form 8-K, a standard filing companies use to inform investors of major events that shareholders should know about. In this case, it included the resignation of a key executive, as well as a major index reconstitution that may affect fund tracking performance. The filing warns of tracking error risk, noting: 'Beginning on June 2, 2025, the Index introduced additional Index Constituents… Under current regulatory restrictions, the Trust is only permitted to hold bitcoin and ether… As a result, the Trust's performance may be materially different from the performance of the Index.' Nasdaq has also filed a proposed rule change (SR-NASDAQ-2025-009) with the SEC that would allow the ETF to formally change its benchmark to the broader Nasdaq Crypto Index™ (NCI), enabling it to hold all nine listed crypto assets including LINK, LTC, and UNI. A decision on that proposal is expected by November 2, 2025. Nasdaq confirms XRP, SOL, ADA, and XLM in benchmark index via new SEC filing first appeared on TheStreet on Jun 9, 2025 This story was originally reported by TheStreet on Jun 9, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Axios
12 hours ago
- Axios
Silicon Valley's not crying for Musk
Few tears will be shed in Silicon Valley or at Big Tech firms over Elon Musk's precipitous fall from White House grace. Why it matters: Musk's brief alliance with President Trump warped the usual dynamics of the relationship between America's most valuable industry and its center of political power. Between the lines: Musk himself is widely admired in tech's corridors of power for Tesla's and SpaceX's innovations — but also widely disliked for his unfulfillable promises, erratic behavior and social media addiction. Now that Musk is suddenly on the outs with Trump, a lot of tech leaders are quietly crossing their fingers that they can get back to dealmaking and policy-setting without worrying about a key competitor whispering in the president's ear. Tech giants can't be sure that whoever replaces Musk as Trump's favorite geek will bring stability or regulatory relief — but Musk wasn't delivering on those fronts either. On the other hand, any follow-through on Trump's threat to strangle the flow of federal dollars to Musk's firms would demonstrate that vendettas are the new normal. Such targeting of one person's business empire with the full force of presidential power would send a chill down any CEO's spine, pro- or anti-Trump. The big picture: Tech leaders see huge opportunities in Washington and government work right now. AI is exploding, defense tech is booming, and crypto firms are chomping at the bit. Plenty of CEOs resented what they saw as the Biden administration's hostility to deals, dedication to strict regulation and aggressive stance on antitrust. Yes, but: The long Republican tradition of business-friendly regulatory positions has mutated into a Trumpian realpolitik. The Trump administration has been forthright in its intention to help friends and punish enemies. Help comes as contracts and preferential treatment by regulators; punishment comes via canceled contracts, fines and even prosecution by the Justice Department. The terms of this week's Trump-Musk feud made starkly clear how serious Trump is about these carrot-and-stick moves. Losers: Musk himself obviously faces not only financial losses but a reputational reckoning. He has already alienated his liberal-left fans, who'd once been drawn to his electric vehicles. If Trump's MAGA loyalists abandon him too, he might be left with a thinned social media fan base, a pile of sinking shares, and not much else. Winners: Virtually any tech leader not named Musk can find satisfaction in his misfortune. Musk's businesses are all deeply entangled with one another but rarely partner with non-Musk-owned firms. His empire is a mostly self-contained Muskiverse, meaning its woes aren't likely to prove contagious. There are plenty of MAGA-friendly tech firms — think Palantir and Anduril in defense tech, Meta under a newly MAGA-fied Mark Zuckerberg, or the Andreessen-Horowitz portfolio in startups — ready to step in to the Musk void in D.C. if he and the president don't patch things up. U.S. leaders may decide it's time to broaden the supply of rockets that can launch satellites and astronauts into space beyond SpaceX — and that could benefit Jeff Bezos and his Blue Origin firm. One of the biggest winners, even though he has largely stayed mum on the Musk/Trump fireworks, is OpenAI's Sam Altman. Musk's role in the Trump administration gave his company an inside track on federal contracts. Altman, who wasn't ever known to be close to Trump, surprised Musk by repackaging his giant Stargate datacenter project as a Trump deal and winning an Oval Office photo op with Trump the day after the new president's inauguration. Altman and Musk have their own feud. Both were among the nonprofit's cofounders, and Musk has sued OpenAI, claiming that under Altman it has abandoned its original AI safety mission. Another winner: Vice President J.D. Vance, who during Musk's White House days seemed to fade into the woodwork, has a chance to reassert his primacy as the Trump administration's ambassador to tech. Still to be seen is where some of the other key tech players in Trumpworld — like White House adviser David Sacks — land when the firestorm subsides. The intrigue: You won't read expressions of tech leaders' relief at Musk's D.C. exit in their posts or interviews. There's nothing to be gained and lots to lose for most executives or investors to take sides in the Trump-Musk war of words. That's why the only sound from tech's normally boisterous social-media gallery has been an occasional wan plea of "be nice and make up." What's next: Trump White House dramas never end, they just go into new seasons.
